ALNY - Alnylam Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
ALNY price evolution
ALNY
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $968.49 | $681.88 | $812.69 | |
| Short term investments | $1656.16 | $1689.4 | $1626.69 | |
| Net receivables | $353.85 | $309.48 | $386.38 | $327.79 |
| Inventory | $75.99 | $83.98 | $93.99 | $89.15 |
| Total current assets | $3355.42 | $3172.86 | $2988.61 | $2982.7 |
| Long term investments | $49.39 | $49.39 | $49.39 | |
| Property, plant & equipment | $703.4 | $715.46 | $718.93 | $725.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $836.78 | $835.78 | $847.18 | |
| Total investments | $1705.55 | $1738.79 | $1676.09 | |
| Total assets | $4205.04 | $4009.63 | $3824.39 | $3829.88 |
| Current liabilities | ||||
| Accounts payable | $70.81 | $73.98 | $78.15 | $55.52 |
| Deferred revenue | $71.41 | $262.36 | $290.93 | |
| Short long term debt | $41.66 | $41.67 | $41.51 | |
| Total current liabilities | $1220.66 | $1055.25 | $941.71 | $967.79 |
| Long term debt | $1023.65 | $1262.04 | $1021.73 | $1263.88 |
| Total noncurrent liabilities | $2957.45 | $3101.95 | $3082.74 | |
| Total debt | $1303.7 | $1301.23 | $1305.39 | |
| Total liabilities | $4172.69 | $4012.7 | $4043.66 | $4050.52 |
| Shareholders' equity | ||||
| Retained earnings | -$7203.98 | -$7092.41 | -$7075.53 | -$7009.59 |
| Other shareholder equity | $1.64 | -$34.64 | $7.82 | -$23.38 |
| Total shareholder equity | -$3.07 | -$219.27 | -$220.64 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $812.69 | $866.39 | $819.98 | $496.58 |
| Short term investments | $1626.69 | $1326.01 | $1615.59 | $1377.82 |
| Net receivables | $327.79 | $237.96 | $198.57 | $102.41 |
| Inventory | $89.15 | $128.96 | $86.36 | $75.2 |
| Total current assets | $2982.7 | $2692.25 | $2808.58 | $2614.78 |
| Long term investments | $49.39 | $49.39 | $40.89 | $40.73 |
| Property, plant & equipment | $725.79 | $738.63 | $733.63 | $706.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $847.18 | $854.11 | $834.73 | $792.28 |
| Total investments | $1676.09 | $1375.4 | $1656.48 | $1418.54 |
| Total assets | $3829.88 | $3546.36 | $3643.3 | $3407.06 |
| Current liabilities | ||||
| Accounts payable | $55.52 | $98.09 | $73.43 | $51.97 |
| Deferred revenue | $290.93 | $235.9 | $301.84 | $352.3 |
| Short long term debt | $41.51 | $41.97 | $40.55 | $36.87 |
| Total current liabilities | $967.79 | $767.91 | $695.71 | $585.27 |
| Long term debt | $1263.88 | $1016.94 | $957.04 | $484.32 |
| Total noncurrent liabilities | $3082.74 | $2936.67 | $2359.39 | $1805.54 |
| Total debt | $1305.39 | $1320.25 | $997.59 | $521.19 |
| Total liabilities | $4050.52 | $3704.58 | $3055.1 | $2390.81 |
| Shareholders' equity | ||||
| Retained earnings | -$7009.59 | -$6569.35 | -$5438.19 | -$4585.37 |
| Other shareholder equity | -$23.38 | -$2.39 | -$33.26 | -$43.62 |
| Total shareholder equity | -$220.64 | -$158.22 | $588.2 | $1016.25 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $500.92 | $659.83 | $494.33 | $439.72 |
| Cost of revenue | $68.67 | $65.98 | $85.86 | |
| Gross Profit | $415.01 | $591.15 | $428.36 | $353.86 |
| Operating activities | ||||
| Research & development | $294.14 | $261 | $272.14 | |
| Selling, general & administrative | $248.4 | $210.8 | $198.12 | |
| Total operating expenses | $491.92 | $542.54 | $471.79 | $470.26 |
| Operating income | $48.61 | -$43.44 | -$116.4 | |
| Income from continuing operations | ||||
| EBIT | $22.09 | -$28.33 | -$106.35 | |
| Income tax expense | $2.91 | $5.72 | $2.35 | $0.18 |
| Interest expense | -$40.07 | $33.26 | $35.25 | $31.34 |
| Net income | ||||
| Net income | -$111.57 | -$16.89 | -$65.94 | -$137.87 |
| Income (for common shares) | -$16.89 | -$65.94 | -$137.87 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1828.29 | $1037.42 | $844.29 | $492.85 |
| Cost of revenue | $310.41 | $168.82 | $140.14 | $78.05 |
| Gross Profit | $1517.89 | $868.6 | $704.14 | $414.8 |
| Operating activities | ||||
| Research & development | $1004.41 | $883.01 | $792.16 | $654.82 |
| Selling, general & administrative | $795.65 | $770.66 | $620.64 | $588.42 |
| Total operating expenses | $1800.06 | $1653.67 | $1412.8 | $1243.24 |
| Operating income | -$282.18 | -$785.07 | -$708.65 | -$828.44 |
| Income from continuing operations | ||||
| EBIT | -$312.3 | -$971.02 | -$709.12 | -$771.1 |
| Income tax expense | $6.72 | $4.16 | $0.68 | $2.68 |
| Interest expense | $121.22 | $155.97 | $143.02 | $84.5 |
| Net income | ||||
| Net income | -$440.24 | -$1131.16 | -$852.82 | -$858.28 |
| Income (for common shares) | -$440.24 | -$1131.16 | -$852.82 | -$858.28 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$16.89 | -$65.94 | -$137.87 | |
| Operating activities | ||||
| Depreciation | $24.69 | $25.49 | $23.97 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $89.29 | $45.35 | $41.99 | |
| Total cash flows from operations | $124.16 | -$81.52 | -$29.8 | |
| Investing activities | ||||
| Capital expenditures | -$8.02 | -$12.97 | -$15.31 | |
| Investments | $41.96 | -$54.65 | -$225.35 | |
| Total cash flows from investing | -$63.93 | $33.94 | -$67.62 | -$240.66 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $132.78 | $25.86 | $30.89 | |
| Net borrowings | ||||
| Total cash flows from financing | $263.16 | $131.5 | $28.91 | $39.23 |
| Effect of exchange rate | $2.03 | -$3.12 | -$9.94 | $10.9 |
| Change in cash and equivalents | $287.61 | $286.47 | -$130.16 | -$220.33 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$440.24 | -$1131.16 | -$852.82 | -$858.28 |
| Operating activities | ||||
| Depreciation | $97.03 | $85.55 | $89.69 | $74.44 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $221.68 | $230.65 | $165.72 | $139.87 |
| Total cash flows from operations | $104.16 | -$541.27 | -$641.69 | -$614.96 |
| Investing activities | ||||
| Capital expenditures | -$62.21 | -$72.06 | -$76.37 | -$70.36 |
| Investments | -$269.7 | $246.11 | -$192.73 | -$359.86 |
| Total cash flows from investing | -$336.35 | $169.35 | -$273.3 | -$435.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $147.46 | $259.36 | $246.27 | $299.98 |
| Net borrowings | $135.39 | $500 | $200 | |
| Total cash flows from financing | $172.13 | $425.75 | $1247.12 | $994.98 |
| Effect of exchange rate | $6.39 | -$7.43 | -$9.02 | $4.92 |
| Change in cash and equivalents | -$53.67 | $46.4 | $323.11 | -$50.58 |
News
Fundamentals
| Market cap | $31.62B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 128.84M |
| Revenue | $2.09B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$332.26M |
| Revenue Q/Q | -33.26% |
| Revenue Y/Y | 21.54% |
| P/E ratio | -95.17 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 15.10 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.58 |
|---|---|
| ROA | -8.38% |
| ROE | N/A |
| Debt/Equity | -18.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.75 |
| Quick ratio | 2.69 |